comprehensive -WSS

comprehensive

author：explore 2025-10-01 15:30:16 - browse：243

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： ReNAgade cuts staff seven months after raising $300 million

WSS

The woman behind the Dana Farber

FDA investigates CAR

FDA approves world's first CRISPR

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Wikipedia

comprehensive

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Pediatric cancer treatments threatened by a new FDA policy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

U.K. Biobank has 500,000 peoples' genome sequences available

The cancer drug shortage isn’t new — and neither are the solutions

After sickle

Guidelines to prevent youth baseball injuries need more muscle

Leukemia patients are helped by Syndax's new type of therapy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Americans' trust in science, scientist continues decline: Report

focus

Spinal cord stimulation reduces pain in amputees, study finds

Despite FDA concern, risk that CAR

ReNAgade cuts staff seven months after raising $300 million

STAT letters to the editor on burnt

What PEPFAR has meant on the ground in Ukraine

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

leisure time

hotspot

knowledge

focus